KIORA PHARMACEUTICALS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities
KIORA PHARMACEUTICALS, INC. (KPRX) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities of $393.80 thousand as of 2016-09-30, per its 10-Q filed 2016-11-01.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Liability Assumed, Liability
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities · last filed 2016-11-01
- 2016-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities $393.80K.
- 2016-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities $393.80K.
- 2016-03-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities $393.80K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities |
|---|---|
| 2016-09-30 | $393.80K 10-Q · filed 2016-11-01 |
| 2016-06-30 | $393.80K 10-Q · filed 2016-08-10 |
| 2016-03-31 | $393.80K 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |